Khaliqs, China does not want any dilution of their stake given the size of the CR would invite compeitors to sit on the register.What China should do is rebid the offer and provide interim working capital as part of the deal.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%